Friday, June 5, 2020
Daewoong Pharmaceutical Focusing on Intractable Disease Treatments
Searching for a ‘Next Nabota’
Daewoong Pharmaceutical Focusing on Intractable Disease Treatments
  • By Choi Moon-hee
  • May 22, 2019, 13:32
Share articles

Daewoong Pharmaceutical's botulinum toxin Nabota

Daewoong Pharmaceutical said on May 21 that CEO Jeon Seung-ho held a meeting of the Daewoong research and development (R&D) committee to call for continuous efforts to develop new drugs.

The Daewoong R&D committee is a governing body for systematic management of Daewoong Pharmaceutical's new drug development efforts. The committee has held a monthly meeting since 2010 with the attendance of the CEO, head of the R&D center, and director of development. The company says it owes the R&D committee the development of Nabota.

Promising drugs under development by the Daewoong R&D committee include the first in class anti-ulcer drug DWP14012 and dry eye treatment HL036. DWP14012 is an acid pump antagonist with a reversible inhibitory mechanism and is expected to be the next generation proton pump inhibitor (PPI), which is widely used in treatment of gastroesophageal reflux disease (GERD). The company completed phase 1 clinical trials in Korea in February 2017 and phase 2 trials in June of the same year. This project won a grant from the Korea Drug Development Fund early last year and is currently in phase 3 clinical trials, aiming for domestic approval in 2020.

In addition, Daewoong Pharmaceutical focuses its efforts on the development of a dry eye treatment. New dry eye treatment HL036 under joint development with its subsidiary Hanall Biopharma is currently in phase 3 clinical trials in the United States. HL036 was improved so that anti-TNF antibody can be used for local diseases and is in the form of eye-drops, in which Hanall Biopharma’s protein replacement technology called the Resistein technology was used.

In addition, Daewoong's PRS fibrosis treatment DWN12088 is a first-in-class new drug that can fundamentally treat heart fibrosis and excessive inflammation that occur after myocardial infarction. In February, it was awarded with clinical and non-clinical research funding by the Korea Drug Development Fund as a new drug candidate of pulmonary fibrosis. Preclinical development has been completed, and preparations for phase 1 clinical trials are under way.

The company plans to announce results of phase 1 clinical trials of SGLT2 diabetes mellitus treatment DWP16001 in the second half of this year at a diabetes conference and present preclinical results of double-target autoimmune disease treatment DWP212525 and DWP213388 at an overseas conference in the second half of the year. Chronic pain treatment Nav 1.7 DWP17061 is under development for inflammatory pain.